Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) COO Jessica Snow sold 2,298 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $4.95, for a total transaction of $11,375.10. Following the completion of the transaction, the chief operating officer now directly owns 254,193 shares of the company's stock, valued at approximately $1,258,255.35. The trade was a 0.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

2seventy bio Price Performance

Shares of 2seventy bio stock remained flat at $4.95 during mid-day trading on Friday. 665,244 shares of the company's stock traded hands, compared to its average volume of 605,066. The company has a market cap of $255.36 million, a PE ratio of -2.66 and a beta of 1.73. 2seventy bio, Inc. has a one year low of $2.29 and a one year high of $5.99. The stock has a fifty day moving average of $2.99 and a 200-day moving average of $3.70.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Erste Asset Management GmbH acquired a new position in 2seventy bio in the third quarter valued at $25,000. Northern Trust Corp increased its stake in shares of 2seventy bio by 1.4% during the 4th quarter. Northern Trust Corp now owns 408,083 shares of the company's stock valued at $1,200,000 after acquiring an additional 5,470 shares during the last quarter. Eversept Partners LP lifted its holdings in shares of 2seventy bio by 0.6% during the 4th quarter. Eversept Partners LP now owns 1,003,678 shares of the company's stock worth $2,951,000 after acquiring an additional 5,599 shares during the period. American Century Companies Inc. boosted its position in shares of 2seventy bio by 6.6% in the fourth quarter. American Century Companies Inc. now owns 93,552 shares of the company's stock worth $275,000 after acquiring an additional 5,785 shares during the last quarter. Finally, Intech Investment Management LLC grew its holdings in 2seventy bio by 41.1% in the fourth quarter. Intech Investment Management LLC now owns 20,688 shares of the company's stock valued at $61,000 after purchasing an additional 6,030 shares during the period. Hedge funds and other institutional investors own 93.90% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Morgan Stanley decreased their price target on shares of 2seventy bio from $6.00 to $5.00 and set an "equal weight" rating for the company in a research report on Friday, March 14th. Leerink Partners reiterated a "market perform" rating and set a $5.00 price target (down from $9.00) on shares of 2seventy bio in a research note on Tuesday, March 11th. Leerink Partnrs lowered 2seventy bio from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 11th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of 2seventy bio in a research note on Friday, March 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $6.67.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.